Table 5.

Univariate Cox regression analysis for local relapse free survival and distant metastasis-free survival free survival

	Local relapse free survival				Distant metastasis-free survival
	HR	95% CI	p-value		HR	95% CI	p-value
IC (reference: CCRT)	1.38	0.71-2.66	0.342		0.35	0.15-0.85	0.02
Stage IVA (reference: III)	2.36	1.15-4.86	0.019		2.22	1.07-4.6	0.032
Stage IVB (reference: III)	1.19	0.47-3.06	0.713		2.34	1.18-4.62	0.015
Stage IV (reference: III)	1.82	0.94-3.51	0.077		2.58	1.28-5.18	0.008
T3 (reference: T1-T2)	2.73	1.02-7.34	0.046		1.02	0.72-1.44	0.93
T4 (reference: T1-T2)	4.64	1.96-10.99	0.001		1.13	0.92-1.39	0.259
T4 (reference: T3)	1.74	0.79-3.82	0.17		1.56	0.53-4.57	0.416
N2 (reference: N0-1)	0.54	0.25-1.16	0.112		0.81	0.51-1.28	0.367
N3 (reference: N0-1)	0.52	0.19-1.44	0.209		1.14	0.84-1.54	0.409
N3 (reference: N2)	0.99	0.4-2.47	0.98		2.33	1.01-5.37	0.048
WHO classification type 1 (reference: 2)	N/A.	N/A	0.989		0.47	0.06-3.42	0.454
Female (reference: male)	0.96	0.46-2.01	0.918		0.57	0.25-1.29	0.176
Age ≥ 50 (reference: < 50)	1.79	0.93-3.47	0.083		1.13	0.58-2.19	0.728
With comorbidity* (reference: no)	2.09	1.09-4.03	0.027		1.34	0.68-2.63	0.402

IC: induction chemotherapy + concurrent chemoradiation; CCRT: concurrent chemoradiation; HR: hazard ratio; CI: confidence interval; WHO: World Health Organization; N/A: not applicable due to great disparity between the two groups; *comorbidity: common comorbidities include chronic diseases involving the heart, vessels, brain, lung, liver, kidneys, or immune system and metabolism such as hypertension and diabetes.